Exploring the Anti-ageing Effects of Metformin in COPD

NCT06999343 | Not Yet Recruiting Phase 3

• 1 other identifier: AMICO
• Study Type: interventional
• Target: 212
• Locations: 0 countries
• Sites: N/A

Brief Summary

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1. Main objective: To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo. Participants will take metformin (850mg) or placebo twice daily for 3 years.

Conditions

COPD

Outcome Measures

Primary Outcomes (2)

• Forced expiratory volume in the first second (FEV1)

  The amount of air expelled during the first second of a maximal expiration, performed after a maximal inspiration.

  At inclusion and at 3-years follow-up

• Carbon monoxide diffusion test (DLCO)

  Pulmonary function test, in which the diffusion of gases through the pulmonary alveoli into the blood is studied.

  At inclusion and at 3-years follow-up

Secondary Outcomes (19)

• Age

  Baseline

• Sex at birth

  Baseline

• Height

  Baseline

• Weight

  Baseline and at 1 year, 2 years and 3 years

• Smoking

  Baseline

Study Arms (2)

Experimental treatment

EXPERIMENTAL

Experimental treatment: Metformin Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700mg twice daily. Pharmaceutical form: 850 mg oral tablet. Duration of treatment: Treatment will last for 3 years.

Drug: Metformin 850Mg Tab

Control treatment

PLACEBO COMPARATOR

Control treatment: Placebo Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice a day. Pharmaceutical form: Tablets with the same appearance as metformin tablets. Duration of treatment: Treatment will last for 3 years.

Other: Placebo

Interventions

Metformin 850Mg Tab DRUG

Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.

Experimental treatment

Placebo OTHER

Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.

Control treatment

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Sign the informed consent form prior to any study-specific procedure.
• Male or female, aged 40 to 75 years, inclusive, at the time of Screening.
• Have a COPD clinic diagnostic according to Global Initiative for Obstructive Lung Disease (GOLD) 2022 with a post-bronchodilator FEV1/FVC \<0.7 at Screening (Visit 1)
• Have a post-bronchodilator FEV1 \>40% ≤ 70% of the predicted value at Screening (Visit 1)
• Smoking history of more than 10 pack/years (\[number of cigarettes smoked per day x number of years smoked\]/20)
• Must have been able to understand and comply with the requirements of the study, as judged by the investigator.
• Have some kind of emphysema (centrolobulillar or paraseptal) reported by an expert radiologist.
• Have a certified decrease of the Lung Function in the last 3 years \>40 ml/ml per year of FEV1.
• Women in childbearing age with negative pregnancy test.

You may not qualify if:

• Participating in another clinic trial with any commercially or investigational biological medicinal product within 4 months prior to Screening.
• Patients who take oral corticosteroids chronically.
• Respiratory track infection history (superior respiratory tract included) and pulmonary exarcerbation within 6 weeks prior to Screening.
• Lung resection or lung volume reduction surgery within 12 months prior to Screening (Visit 1), or lung trasplant history, or, as judged by the investigator, patient may have required a thoracotomy or other lung surgery during the study.
• Known active tuberculosis.
• History of intersticial lung or massive pulmonary thromboembolic disease.
• History of bronchiectasis secondary to respiratory diseasesother than COPD (e.g. cystic fibrosis, Kartagener's syndrome, etc.).
• Any clinically significant disease or disorder (e.g. cardiovascular, gastrointestinal, hepatic, renal (GFR \< 30 ml/min), neurological, musculoskeletal, endocrine, metabolic, psychiatric, and major physical impairment) that, in the opinion of the investigator, could have placed the patient at risk for participation in the study, could have influenced the study results, or could have affected the patient's ability to participate in the study.
• Recent history (within 12 months prior to screening \[Visit 1\]) of myocardial infarction, recent history of heart failure (New York Heart Association \[NYHA\] classes III and IV), pulmonary oedema and/or cardiac arrhythmia.
• History of cancer (within 5 years prior to Visit 1), except non-metastatic skin cancer and non-melanoma.
• Patients who cannot perform spirometry manoeuvres or tolerate plethysmography.
• Contraindications to the use of metformin: allergy to the drug, advanced renal failure (CKD stage 3 and above), patients on dialysis, chronic metabolic or respiratory acidosis or liver cirrhosis.
• Patients with type 2 Diabetes Mellitus with or without previous use of metformin.
• Pregnant women, nursing mothers or women of childbearing age who are not going to use contraceptive methods.

Sponsors & Collaborators

• Fundación Instituto de Investigación Sanitaria de Navarra: lead

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Metformin

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Biguanides; Guanidines; Amidines; Organic Chemicals

Central Study Contacts

Alberto Labiano Tabar

CONTACT

+34 848 42 32 36; alberto.labiano.tabar@navarra.es

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2025
• First Posted: May 31, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): May 1, 2029
• Study Completion (Estimated): September 1, 2029
• Last Updated: May 31, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share